CLINICAL RESEARCH: CORONARY ARTERY DISEASE RISK
Serum Myeloperoxidase Levels Are Associated With the Future Risk of Coronary Artery Disease in Apparently Healthy IndividualsThe EPIC-Norfolk Prospective Population Study
Marijn C. Meuwese, MD*,
Erik S.G. Stroes, MD, PhD*,
Stanley L. Hazen, MD, PhD ,
Joram N. van Miert, BSc*,
Jan Albert Kuivenhoven, PhD*,
Robert G. Schaub, PhD ,
Nicholas J. Wareham, MB, PhD||,
Robert Luben, BSc#,
John J.P. Kastelein, MD, PhD*,
Kay-Tee Khaw, MBBChir# and
S. Matthijs Boekholdt, MD, PhD*, ,*
* Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
Department of Cardiology, Academic Medical Center, Amsterdam, the Netherlands
Department of Cell Biology and the Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic Foundation, Cleveland, Ohio
Wyeth Research, Cambridge, Massachusetts
|| MRC Epidemiology Unit, Cambridge, United Kingdom
# Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom
Manuscript received November 27, 2006;
revised manuscript received February 27, 2007,
accepted March 2, 2007.
* Reprint requests and correspondence: Dr. S. Matthijs Boekholdt, Academic Medical Center, Department of Vascular Medicine (F4-159.2), Meibergdreef 9, P.O. Box 22660, 1100 DD Amsterdam, the Netherlands. (Email: s.m.boekholdt{at}amc.uva.nl).
Objectives: We evaluated whether serum myeloperoxidase (MPO) levels are associated with the risk of future development of coronary artery disease (CAD) in apparently healthy individuals.
Background: An enzyme of the innate immune system, MPO exhibits a wide array of proatherogenic effects. These include induction of oxidative damage to low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and promotion of plaque vulnerability. Recent studies revealed that MPO independently predicts adverse outcomes in patients with chest pain or suspected acute coronary syndrome.
Methods: Myeloperoxidase was measured in baseline samples of a case-control study nested in the prospective EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk population study. Case subjects (n = 1,138) were apparently healthy men and women who developed CAD during 8-year follow-up. Control subjects (n = 2,237), matched for age, gender, and enrollment time, remained free of CAD.
Results: The MPO levels were significantly higher in case subjects than in control subjects and correlated with C-reactive protein (CRP) ( = 0.25; p < 0.001) and white blood cell count ( = 0.33; p < 0.001). Risk of future CAD increased in consecutive quartiles of MPO concentration, with an odds ratio (OR) of 1.49 in the top versus bottom quartile (95% confidence interval [CI] 1.20 to 1.84; p < 0.001). After adjustment for traditional risk factors, the OR in the top quartile remained significant at 1.36 (95% CI 1.07 to 1.73). Elevated MPO levels (>728 pmol/l) similarly predicted increased risk of future CAD among participants with either LDL-cholesterol <130 mg/dl, HDL-cholesterol >50 mg/dl, or CRP <2.0 mg/l (OR 1.52 [95% CI 1.21 to 1.91], 1.59 [95% CI 1.24 to 2.05], and 1.42 [95% CI 1.14 to 1.77)], respectively).
Conclusion: Elevated MPO levels predict future risk of CAD in apparently healthy individuals. This study suggests that inflammatory activation precedes the onset of overt CAD by many years.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | BMI = body mass index | | CAD = coronary artery disease | | CRP = C-reactive protein | | CVD = cardiovascular disease | | HDL = high-density lipoprotein | | LDL = low-density lipoprotein | | MPO = myeloperoxidase | | OR = odds ratio |
|
This article has been cited by other articles:
|
|
|
|
 
A. Undurti, Y. Huang, J. A. Lupica, J. D. Smith, J. A. DiDonato, and S. L. Hazen
Modification of High Density Lipoprotein by Myeloperoxidase Generates a Pro-inflammatory Particle
J. Biol. Chem.,
November 6, 2009;
284(45):
30825 - 30835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Zhang, D.-x. Wang, F. Xiao, J. Li, Z.-s. He, and Y.-l. Wan
The impact of previous or concomitant myocardium revascularization on the outcomes of patients undergoing major non-cardiac surgery
Interactive CardioVascular and Thoracic Surgery,
November 1, 2009;
9(5):
788 - 792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Gururajan, P Gurumurthy, P Nayar, S Babu, A Sarasabharati, D Victor, and K M Cherian
Serum myeloperoxidase: a novel biomarker for evaluation of patients with acute coronary syndrome
Heart Asia,
October 15, 2009;
2009(10):
1 - 6.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J S Rana, M Cote, J-P Despres, M S Sandhu, P J Talmud, E Ninio, N J Wareham, J J P Kastelein, A H Zwinderman, K-T Khaw, et al.
Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study
Heart,
October 15, 2009;
95(20):
1682 - 1687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Wong, H. Gransar, J. Narula, L. Shaw, J. H. Moon, R. Miranda-Peats, A. Rozanski, S. W. Hayes, L. E.J. Thomson, J. D. Friedman, et al.
Myeloperoxidase, Subclinical Atherosclerosis, and Cardiovascular Disease Events
J. Am. Coll. Cardiol. Img.,
September 1, 2009;
2(9):
1093 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. W. Tang
Enhancing the Prognostic Value of Cardiac Imaging With Multimodal Risk Assessment
J. Am. Coll. Cardiol. Img.,
September 1, 2009;
2(9):
1100 - 1102.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ronald, J. W. Chen, Y. Chen, A. M. Hamilton, E. Rodriguez, F. Reynolds, R. A. Hegele, K. A. Rogers, M. Querol, A. Bogdanov, et al.
Enzyme-Sensitive Magnetic Resonance Imaging Targeting Myeloperoxidase Identifies Active Inflammation in Experimental Rabbit Atherosclerotic Plaques
Circulation,
August 18, 2009;
120(7):
592 - 599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Ali, P. Sarcia, T. H Mosley, V. Kondragunta, and I. J Kullo
Association of serum myeloperoxidase with the ankle-brachial index and peripheral arterial disease
Vascular Medicine,
August 1, 2009;
14(3):
215 - 220.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. K. Schindhelm, L. P. van der Zwan, T. Teerlink, and P. G. Scheffer
Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification?
Clin. Chem.,
August 1, 2009;
55(8):
1462 - 1470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Talati, K. M Reinhart, C M. White, O. J Phung, A. Sedrakyan, J. Kluger, and C. I Coleman
Outcomes of Perioperative {beta}-Blockade in Patients Undergoing Noncardiac Surgery: A Meta-Analysis
Ann. Pharmacother.,
July 1, 2009;
43(7):
1181 - 1188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Nicholls and S. L. Hazen
Myeloperoxidase, modified lipoproteins, and atherogenesis
J. Lipid Res.,
April 1, 2009;
50(Supplement):
S346 - S351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Rana, B. J. Arsenault, J.-P. Despres, M. Cote, P. J. Talmud, E. Ninio, J. W. Jukema, N. J. Wareham, J. J.P. Kastelein, K.-T. Khaw, et al.
Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women
Eur. Heart J.,
February 18, 2009;
(2009)
ehp010v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. El Harchaoui, B. J. Arsenault, R. Franssen, J.-P. Despres, G. K. Hovingh, E. S.G. Stroes, J. D. Otvos, N. J. Wareham, J. J.P. Kastelein, K.-T. Khaw, et al.
High-Density Lipoprotein Particle Size and Concentration and Coronary Risk
Ann Intern Med,
January 20, 2009;
150(2):
84 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. K. Rudolph, V. Rudolph, and S. Baldus
Contribution of Myeloperoxidase to Smoking-dependent Vascular Inflammation
Proceedings of the ATS,
December 1, 2008;
5(8):
820 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Johnston, H. Dargie, and A. Jardine
Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease
Heart,
August 1, 2008;
94(8):
1080 - 1088.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weber and C. Hamm
Novel biomarkers--the long march from bench to bedside
Eur. Heart J.,
May 1, 2008;
29(9):
1079 - 1081.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. L. Gornik
Peripheral arterial disease enters the biomarker era. Does risk stratification tell us something that we don't already know?
Eur. Heart J.,
January 2, 2008;
29(2):
150 - 152.
[Full Text]
[PDF]
|
|
|
|
